376 related articles for article (PubMed ID: 18379024)
1. [Mechanisms for formation of myeloma bone disease].
Yata K; Abe M; Matsumoto T
Clin Calcium; 2008 Apr; 18(4):438-46. PubMed ID: 18379024
[TBL] [Abstract][Full Text] [Related]
2. [Bone disease in multiple myeloma and its mechanism].
Abe M
Clin Calcium; 2006 Apr; 16(4):565- 71. PubMed ID: 16582506
[TBL] [Abstract][Full Text] [Related]
3. [Cytokines in bone diseases. Cytokines and myeloma bone disease].
Abe M
Clin Calcium; 2010 Oct; 20(10):1474-80. PubMed ID: 20890028
[TBL] [Abstract][Full Text] [Related]
4. [Myeloma bone disease and RANKL signaling].
Abe M
Clin Calcium; 2011 Aug; 21(8):1167-74. PubMed ID: 21814021
[TBL] [Abstract][Full Text] [Related]
5. [Cytokines and myeloma bone disease].
Abe M
Clin Calcium; 2014 Jun; 24(6):871-8. PubMed ID: 24870838
[TBL] [Abstract][Full Text] [Related]
6. [Mutual interaction between myeloma cells and bone marrow microenvironment].
Abe M
Rinsho Ketsueki; 2009 Jun; 50(6):453-60. PubMed ID: 19571504
[No Abstract] [Full Text] [Related]
7. Bone destruction in multiple myeloma.
Matsumoto T; Abe M
Ann N Y Acad Sci; 2006 Apr; 1068():319-26. PubMed ID: 16831932
[TBL] [Abstract][Full Text] [Related]
8. TGF-β-related mechanisms of bone destruction in multiple myeloma.
Matsumoto T; Abe M
Bone; 2011 Jan; 48(1):129-34. PubMed ID: 20570621
[TBL] [Abstract][Full Text] [Related]
9. MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells.
Oba Y; Lee JW; Ehrlich LA; Chung HY; Jelinek DF; Callander NS; Horuk R; Choi SJ; Roodman GD
Exp Hematol; 2005 Mar; 33(3):272-8. PubMed ID: 15730850
[TBL] [Abstract][Full Text] [Related]
10. Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease.
Heider U; Hofbauer LC; Zavrski I; Kaiser M; Jakob C; Sezer O
Biochem Biophys Res Commun; 2005 Dec; 338(2):687-93. PubMed ID: 16216218
[TBL] [Abstract][Full Text] [Related]
11. Osteoblast function in myeloma.
Roodman GD
Bone; 2011 Jan; 48(1):135-40. PubMed ID: 20601285
[TBL] [Abstract][Full Text] [Related]
12. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
13. Role of osteoblast suppression in multiple myeloma.
Stewart JP; Shaughnessy JD
J Cell Biochem; 2006 May; 98(1):1-13. PubMed ID: 16440324
[TBL] [Abstract][Full Text] [Related]
14. Current insights into the role of transforming growth factor-beta in bone resorption.
Fox SW; Lovibond AC
Mol Cell Endocrinol; 2005 Nov; 243(1-2):19-26. PubMed ID: 16219413
[TBL] [Abstract][Full Text] [Related]
15. Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma.
Abe M; Hiura K; Wilde J; Moriyama K; Hashimoto T; Ozaki S; Wakatsuki S; Kosaka M; Kido S; Inoue D; Matsumoto T
Blood; 2002 Sep; 100(6):2195-202. PubMed ID: 12200385
[TBL] [Abstract][Full Text] [Related]
16. [Link between osteoclastogenesis, angiogenesis and myeloma expansion].
Abe M
Clin Calcium; 2008 Apr; 18(4):473-9. PubMed ID: 18379029
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of bone lesions in multiple myeloma.
Bataille R; Chappard D; Klein B
Hematol Oncol Clin North Am; 1992 Apr; 6(2):285-95. PubMed ID: 1582975
[TBL] [Abstract][Full Text] [Related]
18. Role of the bone marrow microenvironment in multiple myeloma.
Roodman GD
J Bone Miner Res; 2002 Nov; 17(11):1921-5. PubMed ID: 12412796
[TBL] [Abstract][Full Text] [Related]
19. Macrophage inflammatory protein-1 delta: a novel osteoclast stimulating factor secreted by renal cell carcinoma bone metastasis.
Kominsky SL; Abdelmagid SM; Doucet M; Brady K; Weber KL
Cancer Res; 2008 Mar; 68(5):1261-6. PubMed ID: 18316587
[TBL] [Abstract][Full Text] [Related]
20. New potential targets for treating myeloma bone disease.
Roodman GD
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6270s-6273s. PubMed ID: 17062712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
